Back
Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.
Journal article

Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.

  • Minicozzi P Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Van Eycken L Research Department, Belgian Cancer Registry, Brussels, Belgium.
  • Molinie F Loire-Atlantique/Vendée Cancer Registry, Nantes, France.
  • Innos K Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.
  • Guevara M Navarra Cancer Registry, Public Health Institute of Navarra, IDISNA, Pamplona, Spain.
  • Marcos-Gragera R Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Castro C Department of Epidemiology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Rapiti E Geneva Cancer Registry, Global Health Institute, University of Geneva, Geneva, Switzerland.
  • Katalinic A University of Lübeck, Institute for Social Medicine and Epidemiology, Lübeck, Germany.
  • Torrella A Castellón Cancer Registry, Epidemiology Unit, Public Health Department, Castellón, Spain.
  • Žagar T Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  • Bielska-Lasota M Department of Health Promotion and Prevention of Chronic Diseases, National Institute of Public Health (NIH), Warsaw, Poland.
  • Giorgi Rossi P Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Larrañaga N Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Bastos J EpiUnit, Institute of Public Health, University of Porto, Porto, Portugal.
  • Sánchez MJ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Sant M Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Show more…
  • 2018-11-10
Published in:
  • International journal of cancer. - 2019
comorbidities
early breast cancer
outcomes
population study
standard treatment
Adolescent
Adult
Age Factors
Aged
Breast Neoplasms
Combined Modality Therapy
Comorbidity
Europe
Female
Humans
Mammaplasty
Mastectomy, Segmental
Middle Aged
Radiotherapy, Adjuvant
Time-to-Treatment
Treatment Outcome
Young Adult
English Survival for breast cancer (BC) is lower in eastern than northern/central Europe, and in older than younger women. We analysed how comorbidities at diagnosis affected whether selected standard treatments (STs) were given, across Europe and over time, also assessing consequences for survival/relapse. We analysed 7581 stage I/IIA cases diagnosed in 9 European countries in 2009-2013, and 4 STs: surgery; breast-conserving surgery plus radiotherapy (BCS + RT); reconstruction after mastectomy; and prompt treatment (≤6 weeks after diagnosis). Covariate-adjusted models estimated odds of receiving STs and risks of death/relapse, according to comorbidities. Pearson's R assessed correlations between odds and risks. The z-test assessed the significance of time-trends. Most women received surgery: 72% BCS; 24% mastectomy. Mastectomied patients were older with more comorbidities than BCS patients (p < 0.001). Women given breast reconstruction (25% of mastectomies) were younger with fewer comorbidities than those without reconstruction (p < 0.001). Women treated promptly (45%) were younger than those treated later (p = 0.001), and more often without comorbidities (p < 0.001). Receiving surgery/BCS + RT correlated strongly (R = -0.9), but prompt treatment weakly (R = -0.01/-0.02), with reduced death/relapse risks. The proportion receiving BCS + RT increased significantly (p < 0.001) with time in most countries. This appears to be the first analysis of the influence of comorbidities on receiving STs, and of consequences for outcomes. Increase in BCS + RT with time is encouraging. Although women without comorbidities usually received STs, elderly patients often received non-standard less prompt treatments, irrespective of comorbidities, with increased risk of mortality/relapse. All women, particularly the elderly, should receive ST wherever possible to maximise the benefits of modern evidence-based treatments.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/252378
Statistics
Document views: 25 File downloads: